Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Camilly P. Pires de Mello"'
Publikováno v:
Viruses, Vol 13, Iss 5, p 771 (2021)
Dengue virus (DENV) is a flavivirus associated with clinical manifestations ranging in severity from self-limiting dengue fever, to the potentially life threatening condition, severe dengue. There are currently no approved antiviral therapies for the
Externí odkaz:
https://doaj.org/article/79be2d47a6124270b23273c0c4d37860
Autor:
Camilly P. Pires de Mello, George L. Drusano, Jaime L. Rodriquez, Ajeet Kaushik, Ashley N. Brown
Publikováno v:
Viruses, Vol 10, Iss 6, p 317 (2018)
Dengue virus (DENV) is the most prevalent mosquito-borne viral illness in humans. Currently, there are no therapeutic agents available to prevent or treat DENV infections. Our objective was to fill this unmet medical need by evaluating the antiviral
Externí odkaz:
https://doaj.org/article/4c859b6c22a947bfbabc74ee8cc75a47
Autor:
Izabel Christina Nunes de Palmer Paixão, Viveca Giongo, Camilly Pestana Pires de Mello, Felipe Mateini, Juliana Barbosa, Jussara Pinheiro Barbosa, Beatriz Grosso Fleury, Clovis Barreira e Castro, Angelo da Cunha Pinto
Publikováno v:
DST, Vol 28, Iss 1 (2022)
Introduction: Latency and resistance of acyclovir-resistant strains of Herpes simplex virus type 1 (HSV-1) have been associated with serious sequelae in immunocompromised individuals, such as AIDS patients. Consequently, the search for new substances
Externí odkaz:
https://doaj.org/article/b31a8e7fd1aa49169128f133a2d98413
Autor:
Camilly P. Pires de Mello, Carlos Carmona-Moran, Christopher W. McAleer, Julian Perez, Elizabeth A. Coln, Christopher J. Long, Carlota Oleaga, Anne Riu, Reine Note, Silvia Teissier, Jessica Langer, James J. Hickman
Publikováno v:
Lab Chip
Body-on-a-chip in vitro systems are a promising technology that aims to increase the predictive power of drug efficacy and toxicity in humans when compared to traditional animal models. Here, we developed a new heart-liver body-on-a-chip system with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddd99dfc816c65003bd4885bcce6c968
https://doi.org/10.1039/c9lc00861f
https://doi.org/10.1039/c9lc00861f
Publikováno v:
Drug Discov Today
Drug development for rare diseases, classified as diseases with a prevalence of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07b65dbd049a20bd406a73d9690d42ff
https://doi.org/10.1016/j.drudis.2019.08.001
https://doi.org/10.1016/j.drudis.2019.08.001
Autor:
Camilly P. Pires de Mello, Jonathan R. Adams, George L. Drusano, Robert Kulawy, Matthew Shudt, Ashley N. Brown
Publikováno v:
European Journal of Pharmaceutical Sciences. 111:443-449
Drug-resistant influenza is a significant threat to global public health. Until new antiviral agents with novel mechanisms of action become available, there is a pressing need for alternative treatment strategies with available influenza antivirals.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fcd052f3c90bd1cbc7ed58617af2e05
https://doi.org/10.1016/j.ejps.2017.10.027
https://doi.org/10.1016/j.ejps.2017.10.027
Autor:
Camilly P. Pires de Mello, Thereza Quirico-Santos, Izabel Palmer Paixão, David C. Bloom, Viveca Antonia Giongo Galvão da Silva, Lidia Maria da Fonte de Amorim, Lucianne Madeira Fragel
Publikováno v:
Antiviral therapy. 25(1)
Background Infection by herpes simplex type-1 virus (HSV-1) causes several pathological processes, including cutaneous, oral and genital infections, fatal encephalitis and cognitive dysfunction due to grey matter loss. Acyclovir is the reference comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b10297a08862fe5c7566c0508bb6d5a
https://pubmed.ncbi.nlm.nih.gov/31099756
https://pubmed.ncbi.nlm.nih.gov/31099756
Autor:
Tae Hwan Kim, Ajeet Kaushik, Camilly P. Pires de Mello, Jürgen B. Bulitta, Ashley N. Brown, Xun Tao, Michael Vicchiarelli
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
Zika virus (ZIKV) infection is associated with serious, long-term neurological manifestations. There are currently no approved therapies for the treatment or prevention of ZIKV infection. Favipiravir (FAV) is a viral polymerase inhibitor with broad-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eb781e39d9bb88b86099de81cf1a583
https://doi.org/10.1128/aac.00967-18
https://doi.org/10.1128/aac.00967-18
Autor:
Jaime L. Rodriquez, Tae Hwan Kim, Justin J. Pomeroy, Ashley N. Brown, Camilly P. Pires de Mello, Xun Tao, Jürgen B. Bulitta
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
Zika virus (ZIKV) is a major public health concern due to its overwhelming spread into the Americas. Currently, there are neither licensed vaccines nor antiviral therapies available for the treatment of ZIKV. We aimed to identify and rationally optim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baef147fad41f6917e5404cbe320e99c
https://doi.org/10.1128/aac.01983-17
https://doi.org/10.1128/aac.01983-17
Publikováno v:
Antiviral Therapy. 21:277-286
Infection by herpes simplex virus type-1 (HSV-1) causes several diseases, ranging from cutaneous, oral and genital infections to fatal encephalitis. Despite the availability of antiviral therapies on the market, their efficacies are incomplete, and n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ae9e749b6f6abbe9ee09d01debd40dd
https://doi.org/10.3851/imp3018
https://doi.org/10.3851/imp3018